Mark Allen, Daniel Von Hoff, Raymond Woosley, Ernst Mayr, Scott Garrett, and John Reed | GenomeWeb

Tripos Discovery Research has promoted Mark Allen to senior vice president and managing director. Allen succeeds Peter Hecht, who will become CEO of Oridis Biomed, but will remain a Tripos scientific advisor. Allen was previously head of drug discovery support for Novartis Pharma UK, where he was head of drug discovery support. Prior to that position, Allen worked at CIBA-Geigy Pharma UK, and was eventually appointed head of core drug technologies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.